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Abstract
Background: The correct understanding of the biochemical and metabolic interactions between coronary risk
factors contribute to the exploration of cardiovascular pathophysiology and improves therapeutic care.
The aim of this study was to explore the endothelin-1 (ET-1) concentration and the angiotensin converting enzyme
(ACE) activity among Tunisian patients with coronary heart disease, and to investigate the metabolic relationships
between these two markers,… and to assess the possible relationship between them and the different risk factors.
In this present study, ET-1 concentration was determined by an analytical method (High Performance Chromatography,
coupled by Mass Spectrometry), ACE activity was measured by a kinetic method for patients and healthy controls.
These subjects (157 patients and 142 controls) beneficed also by a biochemical exploration (lipid, apolipoproteins and
glucose profiles) to quantify cardiovascular risk.
Results: A statistically significant increase of the ET-1 concentration was found among patients compared to healthy
controls (15.2 ± 5.3 nM vs 7.1 ± 2.7 nM, p < 0,00001). For the ACE activity, in spite the treatment of the majority of
patients (97%) with ACE inhibitors, this activity was statistically elevated in patients compared to healthy subjects (86.7
± 25.4 IU/L vs 42.8 ± 12.1 IU/L, p < 0.00001).
Furthermore, a statistically positive correlation was identified between these two cardiac markers (r = 0.68 p < 0.00001).
Conclusion: The study of the metabolic relationship between the ET-1 and ACE among coronary patients reveals other
therapeutics targets.
Keywords: Acute coronary syndrome, Endothelin-1, Angiotensin-converting enzyme, Risk factors, Metabolic
interactions
Background
Acute Coronary Syndrome (ACS) is classified among the
major cause of mortality and morbidity in the western
countries. The diagnosis of this ischemic syndrome is
essentially based on clinical examination (electrocardio-
gram), the biological examination (serum level of cardiac
troponin) is used to identify the necrotic damage. This
disease is multifactorial, complex and polygenic. The risk
factors are varied and diversified, according to the
Framingham reference study; these factors are classified
into modifiable factors (smoking, arterial hypertension,
diabetes, obesity …) and un-modifiable factors (age, gen-
der, heredity…). Atherosclerosis is the main etiology of
this syndrome [1–4].
However, the endothelin-1 (ET-1) and the hyperactivity
of the angiotensin- converting enzyme (ACE) are classi-
fied among the coronary “unconventional risk factors”
[5–7].
ET-1 is an endothelium derived, potent vasocon-
strictor peptide of 21 amino acids (2.5 kDa with a great
structural homology with snake venom, the S6
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sarafotoxin). It was finally isolated and sequenced from
endothelial cell culture by Yanagisiwa M. in 1988. Its
peptide is strongly implicated in the ACS’s genesis and
complications by its vasoconstrictors, pro-oxidant and
thrombotic effects [7–9].
ACE (peptidyl-dipeptidase with zinc, EC, 3,4,15,1) is
well known by its physiological role in the rennin
angiotensin system by its role in angiotensin-I cleaving
(an inactive decapeptide) to generate angiotensin II (a
powerful vasoconstrictor) and its role in bradykinin
hydrolysis (a potent vasodilatator). This enzyme stimu-
lates also the release of aldosterone from the adrenal
cortex, leading to sodium retention [10–12].
In this context, comes the aim of our study which is to
quantify the serum concentrations of ET-1 and to meas-
ure the ECA serum activity in Tunisians coronary com-
pared to controls subjects, investigate the impact of
various risk factors on serum variation of these two
parameters as well as the study of the correlation
between these two vasoconstrictors.
Methods
Populations study
This is a prospective study, in which sampling was carried
between January 2010 and November 2011. One hundred
fifty seven Tunisian coronary patients (121 men and 36
women) middle-aged (64.8 ± 11.7 years) were recruited
from the Cardiology Service of Farhat Hached, Hospital of
Sousse, Tunisia. One hundred forty two healthy subjects
(111 men and 31 women) middle-aged (56.8 ± 9.4 years)
were considered as the control group. This age difference
is unavoidable, since at a more advanced age, the risk
factors accumulate, and the possibility to find healthy sub-
jects non carriers of any risk factor becomes almost
impossible (since the advanced age it is even a risk factor).
So we were here between two choices: either having
patients and "healthy subjects" holders of risk factors with
a close age, or having a remarkable difference (not signifi-
cant) of age and healthy controls without risk factors.
The patients and healthy subjects signed a free and
clear consent which explains the objectives of this work
with an undertaking not to publish the names of partici-
pants, their personal data including test results (follow-
ing the instructions of Tunisian National Committee of
Medical Ethics, consistent with the Declaration of
Helsinki).
The approval of compliance with the Helsinki declar-
ation was signed in December 2009. A datasheet had
been prepared for each subject (patient or control) to
identify cardiovascular risk factors and to know the sus-
ceptibility degrees to ACS. This sheet contains the an-
thropometric characteristics, the biological parameters,
the risk factors, the treatments of patients, the exclusion
factors (thyroid diseases, sarcoidosis, Gaucher disease).
Laboratory analysis
Venous blood samples were drawn after 12 h overnight
fast. A collection of two tubes were made for each
patient and witness: one tube without anticoagulant for
determination lipid parameters, ET-1 concentration, and
ACE activity and, the second one is heparinized tube for
blood glucose. Serum total cholesterol (TC), triglycerides
(TG), high density lipoprotein cholesterol (HDL-C) and
glucose were measured with colorimetric essay using an
automated system (Cx9 Pro-Beckman Coulter-Fuller-
Ton CA). Low density lipoprotein cholesterol (LDL-C)
was determined by Friedewald formula for TG levels
below 4.5 mmol/L. Apolipoproteins (ApoA1 and Apo B)
were determined by immunonephelometry (Cobas Inte-
gra 400, Roche).
After plasmatic ET-1 extraction with ethanol, the con-
centration was measured by High Performance Chroma-
tography, coupled to Mass Spectrometry (3200 Q TRAP
LC/MS/MS system),according the Walczak M protocol,
2010 [9],using a synthetic standard (ET-1 Sigma-Aldrich
St. Louis, MO, USA) for the specific spectra identifica-
tion and for the calibration curve determining. Chroma-
tographic separation was carried out with C18 analytical
column (30 mm x 2.1 mm, 3.5 μm, Waters Ireland) set
at 20 °C. Two solvents mixtures were used: solvent A:
Acetonitrile and solvent B: H2O. The following gradient
was used: 0–5 min 0–100% A; 5–7 min 100% A; 7–8,
100–0% A; 8–15 min, 100% B. The flow rate was set at
300 μlmin−1 and a sample volume of 25 μl was injected
in the analytical column. The linearity zone (1.6 nM -
160 nM) is established after calibrationby a purified
bovine serum (with 3 repetitions for each concentration)
ACE activity was determined by kinetic method at
340 nm, according the Chalghoum A protocol, 2012 [4],
using a synthetic substrate, Furylacryloyl-phenylalanyl–
glycyl-glycine (FAPGG) (Trinity Biotech,St Louis USA),
with an initial measurement at t = 0 min and a final
measurement at t = 5 min.
Statistical analysis
Database management and statistical analyseswere
carried out using SPSS (Statistical Package forthe
Sociological Sciences), version 21.0 (IBM). Results are
presented as means ± SD, or percentages. Means were
compared using Student test. The relations between
variables were assessed with Pearson’s correlation
analysis.
These parametric tests (means comparison, statis-
tical correlations) were performed under of the ana-
lytical statistics conditions (Gaussian dispersion for
the different parameters, n ≥ 30 for each group and
subgroup…). The significance threshold was set at 5%
(p < 0.05).
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Results
Table 1 summarizes the anthropometric and clinical data
of patients and health subjects. Hypertension, diabetes,
obesity, tobacco, heredity… are the majors risk factors.
However our control subjects are not exposed to these
factors
Biological parameters and the values of ET-1 and ACE
in patients and controls subjects are shown in Table 2.
Glucose, TC, LDL-C,and apolipoprotein B(Apo B)
were significantly increased in patients compared to
controls. Unlike apolipoprotein A1 concentration was
significantly higher among control group compared to
patients. HDL-C, and TG showed no significant differ-
ence between two populations.
Figure 1 illustrates the mass spectra of the ET-1
peptide, triply ionized, 832.4 Da (M / Z).
In our study, a statistically significant elevation of the
ET-1 concentration was observed among patients com-
pared to healthy subjects. For the ACE activity, although
the majority of our patients (97%) were treated with
ACE inhibitors, this activity was statistically elevated in
patients compared to controls subjects.
Biochemical exploration showed that these two vasocon-
strictors depend on gender, arterial hypertension, tobacco,
obesity and dyslipidemia, unlike diabetes, Personal cardio-
vascular antecedents, alcohol intake and physical inactivity
(Tables 3 and 4).
Besides to that, a positive statistically correlation was
founded (r = 0.68 p < 0.00001) between the ET-1 concen-
tration and ACE activity (Fig. 2).
Discussion
Varied risk factors among patients confirm the multifac-
torial and polygenic origin of the ACS, well explained by
the Framingham study [13, 14]. Partially balanced lipid
profile in patients is caused by the diet, recommended
by medical staff, by lipid-lowering therapy and in par-
ticular by the beneficial impact of the ACE inhibitors
that enhance of the glucose sensitivity and the correc-
tion of lipid metabolism [14, 15].
Increased concentration of apolipoprotein B consoli-
dates its atherogenic effects and its involvement in the
genesis of ACS, although the majority of patients are
under statins and anti-hypertensive medication. Unlike
reversible dyslipidemia (only related to diet and lifestyle),
easy to corrected by statins, mixed and genetic dyslipid-
emia requires a combined medication (statins + fibrates,
or nicotinic acid) whereas Apo A1 (statistically higher in
healthy croup) has acardio-protective effect supported
by various studies. These apolipoproteins are under gen-
etic control which showed the polygenic origin of ACS
[4, 14, 16].
Table 1 Anthropometric characteristics and clinical data of





Age (x ± σ years) 64.8 ± 11.7 56.8 ± 9.4
Sex
Men (%) 121 (77%) 111 (78.2%)
Women (%) 36 (23%) 31 (21.8%)
BMI (kg /m2) 27.6 ± 4 23.3 ± 2.2
Hypertension (%) 88 0
Obesity (%) 52 8.5%
Diabetes (%) 64 0
Smoking (%) 62.4 7
Family cardiachistory (%) 68 6
Personnel cardiachistory (%) 66 0
Postmenopausal women (%) 100 82
Dyslipidemia (%) 40 0
Sedentary (%) 43 11
Alcohol (%) 33 14
Treatment : ACE inhibitors (%) 97 0
Statins (%) 38 0
Beta-Blockers (%) 33
Ca-Blockers (%) 27 0
Diuretics (%) 17 0
X mean
σ standard deviation
BMI Body mass index
Table 2 The distribution of biological markers, ET-1 concentration








Glucose (x ± σmmolL/) 9.8 ± 4.2 5.40 ± 0.84 <0000.1
TC (x ± σmmol/L) 5.70 ± 3.1 4.60 ± 2.6 <0.00
HDL-C (x ± σmmol/L) 1.14 ± 0.22 1.30 ± 0.41 NS
LDL-C (x ± σmmol/L) 3.60 ± 2.16 2.80 ± 1.4 <0.001
TG (x ± σmmol/L) 1.60 ± 0.9 1.24 ± 0.3 NS
ApoA1 (x ± σ. g/L) 1.41 ± 0.62 1.80 ± 0.2 <0000.1
ApoB (x ± σ. g/L) 1.40 ± 0.81 0.70 ± 0.2 <0000.1
ET-1 (x ± σ. nM) 15.2 ± 5.3 7.1 ± 2.7 <0.00001
ACE (x ± σ. UI/L) 86.7 ± 25.4 42.8 ± 12.1 <0.00001




HDL-C high density lipoprotein cholesterl
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Furthermore, our study showed a statistically signifi-
cant increase in the ET-1 values among patients
compared to control subjects, which reflects its role not
only in prolonged vasoconstriction but also in its athero-
genic impact, its pro-oxidant effect (indirectly involved
in the NADPH oxidase activation and radical oxygen
species generation) and its pro-aggregating role (by his
role in the thromboxane A2 synthesis). [8, 9, 16–18].
Although, 97% patients were under treatment with inhib-
itors of angiotensin-I converting enzyme, this enzyme activ-
ity was statistically higher among patients, reflecting the
involvement of ACE as risk parameters for heart diseases.
This role is well described in the literature and explained
mainly by hypertensive and vasoconstrictor effects of this
zinc-metallopeptidase. Recent studies also have been begin-
ning the study of pro-oxidant role of this enzyme by activa-
tion of NADPH oxidase which triggers lipid peroxidation
starting point for atherosclerosis. Actually vasoconstrictor
and pro-oxidant effects accumulate in the pathophysiology
of atherosclerosis and coronary syndromes [10, 11, 18].
The ET-1 concentration and the ACE activity dependent,
in this study on gender, hypertension, smoking,obesity and
dyslipidemia, unlike diabetes, Personal cardiovascular ante-
cedents, alcohol and physical inactivity.
The increasing concentration of ET-1 and the higher
activity of the ACE in men patients is explained by hor-
monal and metabolic reasons (non-genetic) since they
are encoded by two autosomal genes (6p24.1 for ET-1
and 17q23 for ACE), unlike the angiotensin-2 converting
enzyme encoded by a gene located on the X chromosome.
According to the reference Framingham study, women
are protected against cardiovascular complications com-
pared to men, this protection is manifested by blocking
and inhibiting of atherogenic factors (including ET-1 and
ACE) [19, 20].
The concentration and high activity in hypertensive
compared with normotensive patients is explained by
the vasoconstrictor effect of ET-1 and ECA and their
roles in the sodium reabsorption. In hyperactivity these
regulatory effects become hypertensive [9, 21, 22].
The ET-1 and the ACE inhibitions by tobacco,
obesity and dyslipidemia are explained by the role of
metabolic syndrome, generated by tobacco (mainly
nicotine), complex lipids (among obese and dyslipid-
emic coronary patients). The metabolic syndrome is
directly and indirectly associated with damage of the
endothelial tissue, major secretory of ET-1 and ACE
[23–27].
 +EPI (832.10) CE (10): 1.101 to 2.120 min from Sample 1 (TuneSampleID) of EPI 832.1  MT20130611124820.wiff (Turbo Spray) Max. 2.6e4 cps.
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Fig. 1 The mass spectra presentation of the ET-1 peptide, triply ionized, with a peak of 832.4 Da (M / Z)
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The high percentage of diabetic patients (64%) shows
the impact of this risk factor in the genesis, patho-
physiology and complications of ACS, manifested at
different levels (oxidative and inflammation status,
metabolic and thrombotic disorders…) [24].
However, diabetes was not implicated in the change of
plasmatic ET-1 and ACE activity and complications of
metabolic syndrome due to the used of drug and the
recommended diet [24, 25].
The difference between patients with and without
cardiovascular antecedents for the two parameters is
not significant given the short half time life of ET-1
and ACE, drug interactions and instant regulation of
these parameters (which reaches their the highest
levels during the acute phase) [7, 11, 22].
Statistically positive correlation between ET-1
concentration and ECA activity is explained by the
inductive effect of the angiotensin II (generated by
the ACE) in the synthesis of ET-1 and thecommon
activation axis of vasoconstrictors (hypovolemia,
intervention ofbaro-receptors…). This activation es-
capes from the regulation in these pathological situa-
tions [28–31].
A multidisciplinary study that combines the inter-
actions between enzymes and predictive peptides
according the rupture and the size of the athero-
sclerotic plaque (measured by appropriate technical,
Optical coherence tomography) can better elucidate
the complex pathophysiology of ACS and more
targeted the treatment [30, 32].
Table 4 The variation of the ACE activity among patients
according risk factors
Populations and risk factors ACE (UI/L) p
Gender Men (n = 121) 88 ± 26.1 <0.001
Women (n = 36) 82.4 ± 3.8
Hypertension Yes (n = 138) 91.8 ± 24.7 <0.00001
No (n = 19) 49.9 ± 8.6
Diabetes Yes(n = 101) 86.1 ± 24.4 NS
No (n = 56) 87.8 ± 28.2
Tobacco Yes(n = 98) 71.8 ± 20.1 <0.00001
No (n = 59) 111.5 ± 27.2
Personal cardiovascular
antecedents
Yes (n = 104) 88.2 ± 26.6 NS
No (n = 53) 83.8 ± 24.3
Obesity Yes(n = 82) 80.2 ± 21.4 <0.001
No (n = 75) 93.8 ± 27.4
Dyslipidemia Yes(n = 63) 80.6 ± 19.7 <0.001
No (n = 94) 90.8 ± 28.7
Alcohol Yes (n = 52) 85.9 ± 25.2 NS
No (n = 105) 87.1 ± 25.9
Sedentarity Yes(n = 67) 87.3 ± 24.9 NS
No (n = 90) 86.3 ± 25.6
NS not significant (p > 0.05)
ECA (UI/L)
ET-1 (nM/L)
Fig. 2 The positive correlation between ET-1 concentration and ACE
activity in patients population (r = 0.68, p < 0.00001)
Table 3 The variation of the ET-1 concentration among patients
according risk factors
Populations and risk factors ET-1 (nM/L) p
Gender Men (n = 121) 17.4 ± 4.6 <0.00001
Women (n = 36) 7.8 ± 2.3
Hypertension Yes (n = 138) 16.4 ± 3.3 <0.00001
No (n = 19) 6.6 ± 1.9
Diabetes Yes (n = 101) 15 ± 5.1 NS
No (n = 56) 15.6 ± 3.8
Tobacco Yes (n = 98) 11.6 ± 3 <0.00001
No (n = 59) 21.2 ± 6.1
Personal cardiovascular
antecedents
Yes (n = 104) 15.3 ± 4.4 NS
No (n = 53) 15 ± 2.8
Obesity Yes (n = 82) 12.2 ± 5.3 <0.001
No (n = 75) 18.2 ± 4
Dyslipidemia Yes (n = 63) 11.8 ± 1.6 <0.00001
No (n = 94) 17 .5 ± 4.6
Alcohol Yes (n = 52) 16 ± 4.1 NS
No (n = 105) 14.8 ± 3.8
Sedentarity Yes (n = 67) 15.7 ± 3.7 NS
No (n = 90) 14.9 ± 2.4
NS not significant (p > 0.05)
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Conclusion
Our study shows the impact of the ET-1 higher concentra-
tion and the ACE higher activity in the ACS predispos-
ition and pathophysiology, seen their vasoconstrictors,
pro-oxidant and pro-aggregation roles. A thorough study
of each component seems important to give other
therapeutic targets (ET-1 inhibitors by analogy to ACE
inhibitors…). Besides to that, the study of molecular and
genomics interactions between these two cardiovascular
markers aim to elucidate the different metabolic cascades
(activation and braking).
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